跳至主要内容
临床试验/NCT04136912
NCT04136912终止2 期

High Frame Rate 3-D Super Resolution Ultrasound Microvascular Imaging

UNC Lineberger Comprehensive Cancer Center1 个研究点 分布在 1 个国家目标入组 27 人开始时间: 2022年5月26日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
终止
入组人数
27
试验地点
1
主要终点
Sensitivity of Acoustic Angiography; Breast Imaging

研究概览

简要总结

This is a 3-arm single center study of 45 patients. These cohorts will include 15 breast patients scheduled to undergo a biopsy, and 15 thyroid patients scheduled to undergo fine needle aspiration, biopsy, or thyroidectomy that consent to undergo an acoustic angiography in conjunction with b-mode ultrasound prior to their scheduled biopsy. Prior to imaging clinical patients, the third arm will include 15 healthy volunteers that will be imaged to optimize imaging parameters.

详细描述

Increasing the sensitivity and specificity of diagnostic imaging in patients at high risk for breast or thyroid cancer could provide substantial clinical benefit by improving diagnosis, preventing over-treatment, and reducing healthcare costs. Acoustic angiography is a new type of contrast enhanced ultrasound imaging which is specifically sensitive to microvascular structure and density. It evaluates tumor micro-vasculature and may provide a powerful prognostic tool for the diagnosis of breast cancer, and eventually for treatment evaluation.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Breast Imaging Cohort

Experimental

A total of 15 women with known breast lesions that are already scheduled to undergo a clinical biopsy

干预措施: Definity (Drug)

Breast Imaging Cohort

Experimental

A total of 15 women with known breast lesions that are already scheduled to undergo a clinical biopsy

干预措施: Acoustic Angiography (Device)

Thyroid Imaging Cohort

Experimental

A total of 15 participants with known thyroid lesions that are already scheduled to undergo a clinical biopsy

干预措施: Definity (Drug)

Thyroid Imaging Cohort

Experimental

A total of 15 participants with known thyroid lesions that are already scheduled to undergo a clinical biopsy

干预措施: Acoustic Angiography (Device)

Healthy Volunteers Cohort

Experimental

A total of 15 participants will be included to optimize imaging parameters.

干预措施: Definity (Drug)

Healthy Volunteers Cohort

Experimental

A total of 15 participants will be included to optimize imaging parameters.

干预措施: Acoustic Angiography (Device)

结局指标

主要结局

Sensitivity of Acoustic Angiography; Breast Imaging

时间窗: Baseline

The sensitivity of Acoustic Angiography in the analysis of known breast lesions will be evaluated by comparing image analyses to the pathological results for these lesions. Sensitivity (%) = True Positives (TP)+False Negatives (FN)True Positives (TP)

Specificity of Acoustic Angiography; Breast Imaging (Percent of Negative Scans)

时间窗: Baseline

Specificity of Acoustic Angiography in the analysis of known breast lesions will be evaluated by comparing image analyses to the pathological results for these lesions. Specificity was calculated based on the formula, which is true negative / (true negative + false positive).

Sensitivity of Acoustic Angiography; Thyroid Imaging (Percent of Positive Scans)

时间窗: Baseline

Sensitivity of Acoustic Angiography in the analysis of know thyroid lesions will be evaluated by comparing image analyses to the pathological results for these lesions. The study closed early due to insufficient funding and did not reach target enrollment. No participants were enrolled in Arm 2 (Thyroid Imaging); therefore, no outcome measure results are available.

Specificity of Acoustic Angiography; Thyroid Imaging (Percent of Negative Scans)

时间窗: Baseline

Specificity of Acoustic Angiography in the analysis of known thyroid lesions will be evaluated by comparing image analyses to the pathological results for these lesions. The study closed early due to insufficient funding and did not reach target enrollment. No participants were enrolled in Arm 2 (Thyroid Imaging); therefore, no outcome measure results are available.

次要结局

  • Sensitivity of Acoustic Angiography Compared to Conventional Ultrasound: Breast (Arbitrary Units)(Baseline)
  • Specificity of Acoustic Angiography Compared to Conventional Ultrasound: Breast (Arbitrary Units)(Baseline)
  • Sensitivity of Acoustic Angiography Compared to Conventional Ultrasound: Thyroid (Arbitrary Units)(Baseline)
  • Area Under the Curve of Acoustic Angiography (Arbitrary Units)(Baseline)
  • Radiologist Preference (Arbitrary Units)(Baseline)
  • Specificity of Acoustic Angiography Compared to Conventional Ultrasound: Thyroid (Arbitrary Units)(Calculated once all imaging is complete [Anticipated 1.5 years])

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

已完成
3 期
Imaging Study to Investigate Safety and Diagnostic Performance of 18F rhPSMA 7.3 PET Ligand in Suspected Prostate Cancer RecurrenceProstate Cancer
NCT04186845Blue Earth Diagnostics391
已完成
3 期
Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer.Prostate Cancer
NCT04186819Blue Earth Diagnostics356
进行中(未招募)
1 期
A clinical study that will test whether cobimetinib plus atezolizumab and atezolizumab alone are effective and safe in patients with colorectal cancer that has spread when compared to regorafenibThe patient population are patients with metastatic or locally advanced unresectable colorectal adenocarcinoma that have received at least two lines of chemotherapy in this setting. The patients must have received 5-FU, oxaliplatin, and irinotecan. Patients who have received an anti-VEGF and anti-EGFR are eligible.MedDRA version: 20.0 Level: PT Classification code 10052358 Term: Colorectal cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10061451 Term: Colorectal cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2016-000202-11-BEF. Hoffman-La Roche Ltd.363
进行中(未招募)
1 期
A clinical study that will test whether cobimetinib plus atezolizumab and atezolizumab alone are effective and safe in patients with colorectal cancer that has spread when compared to regorafenibThe patient population are patients with metastatic or locally advanced unresectable colorectal adenocarcinoma that have received at least two lines of chemotherapy in this setting. The patients must have received 5-FU, oxaliplatin, and irinitecan. Patients who have received an anti-VEGF and anti-EGFR are eligible.MedDRA version: 19.0Level: PTClassification code 10052358Term: Colorectal cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: PTClassification code 10061451Term: Colorectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2016-000202-11-DEF. Hoffman-La Roche Ltd.360
进行中(未招募)
1 期
A clinical study that will test whether cobimetinib plus atezolizumab and atezolizumab alone are effective and safe in patients with colorectal cancer that has spread when compared to regorafenibThe patient population are patients with metastatic or locally advanced unresectable colorectal adenocarcinoma that have received at least two lines of chemotherapy in this setting. The patients must have received 5-FU, oxaliplatin, and irinotecan. Patients who have received an anti-VEGF and anti-EGFR are eligible.MedDRA version: 20.0Level: PTClassification code 10052358Term: Colorectal cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10061451Term: Colorectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2016-000202-11-GBF. Hoffman-La Roche Ltd.363